What Soligenix’s Q1 update reveals about biotech risk after a failed confirmatory trial
HyBryte’s setback leaves Soligenix with cash, orphan assets, and a harder question. Can SGX945 reset the rare disease story?
How Soligenix is trying to turn tolerability and treatment logistics into a differentiated regulatory and commercial story
Soligenix published HyBryte versus Valchlor data in CTCL. Read what it changes for approval, adoption, and competitive positioning.
Asieris Pharmaceuticals launches CEVIRA in China, challenging surgical dominance in CIN2 therapy
China approves CEVIRA, the first non-invasive therapy for CIN2 cervical precancer. Discover what this means for treatment pathways and global adoption.
Biofrontera targets U.S. label expansion for Ameluz in trunk and extremities
Phase 1 PK data bring Ameluz closer to broader FDA review. Explore the regulatory stakes and market impact in actinic keratosis.
What Biofrontera’s Phase 3 results mean for non-facial actinic keratosis treatment strategies
Biofrontera reports positive Phase 3 Ameluz data outside the face and scalp. Find out how this could change actinic keratosis treatment.